Micro-RNAs targeting the estrogen receptor alpha involved in endocrine therapy resistance in breast cancer.
J M M��rquez-Mendoza, N Baranda-��vila, M Lizano, E Langley
Author Information
J M M��rquez-Mendoza: Programa de Doctorado en Ciencias Biom��dicas, Universidad Nacional Aut��noma de M��xico, Ciudad Universitaria, Mexico City 04510, Mexico.
N Baranda-��vila: Unidad de Investigaci��n Biom��dica en C��ncer, Subdirecci��n de Investigaci��n B��sica, Instituto Nacional de Cancerolog��a, Mexico City 14080, Mexico.
M Lizano: Unidad de Investigaci��n Biom��dica en C��ncer, Subdirecci��n de Investigaci��n B��sica, Instituto Nacional de Cancerolog��a, Mexico City 14080, Mexico; Departamento de Medicina Gen��mica y Toxicolog��a Ambiental, Instituto de Investigaciones Biom��dicas, Universidad Nacional Aut��noma de M��xico, Ciudad Universitaria, Mexico City 04510, Mexico.
E Langley: Unidad de Investigaci��n Biom��dica en C��ncer, Subdirecci��n de Investigaci��n B��sica, Instituto Nacional de Cancerolog��a, Mexico City 14080, Mexico. Electronic address: langleyemx@gmail.com.
Endocrine therapy resistance (ETR) in breast cancer (BC) is a multicausal phenomenon with diverse alterations in the tumor cell interactome. Within these alterations, non-coding RNAs (ncRNAs) such as micro-RNAs (miRNAs) modulate the expression of tumor suppressor genes and proto-oncogenes, such as the ESR1 gene encoding estrogen receptor alpha (ER��). This work aims to review the effects of miRNAs targeting ER�� mRNA and their mechanisms related to ETR in BC. A thorough review of the literature and an in silico study were carried out to elucidate the involvement of each miRNA, thus contributing to the understanding of ETR in BC.
